1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,850 | 10,000 | 09:16 | |
| 9,850 | 10,000 | 09:16 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.03. | BayWa r.e, Elicio and BW Ideol open Buchan hub | 64 | reNews | ||
| 17.03. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 4 | GlobeNewswire (USA) | ||
| 16.03. | Elicio Therapeutics kündigt "At-the-Market"-Aktienprogramm im Volumen von 100 Millionen US-Dollar an | 1 | Investing.com Deutsch | ||
| 12.03. | Elicio Therapeutics reports FY GAAP EPS of -$2.58 | 2 | Seeking Alpha | ||
| 12.03. | Elicio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.03. | Elicio Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| ELICIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.03. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.03. | Rodman & Renshaw initiates Elicio Therapeutics stock with buy rating | 1 | Investing.com | ||
| 09.03. | Rodman & Renshaw startet Coverage für Elicio Therapeutics mit Kaufempfehlung | 3 | Investing.com Deutsch | ||
| 18.02. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 8 | GlobeNewswire (USA) | ||
| 16.01. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 10 | GlobeNewswire (USA) | ||
| 19.11.25 | Elicio Therapeutics appoints Marc Wolfgang as chief technology officer | 1 | Investing.com | ||
| 19.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer | 455 | GlobeNewswire (Europe) | BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 13.11.25 | Elicio Therapeutics GAAP EPS of -$0.60 misses by $0.12 | 2 | Seeking Alpha | ||
| 13.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | 227 | GlobeNewswire (Europe) | In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ("PDAC"), fewer disease progressions and deaths than projected have been observed as... ► Artikel lesen | |
| 07.11.25 | Elicio meldet starke Immunantworten in Phase-2-Studie zu KRAS-Krebsimpfstoff | 1 | Investing.com Deutsch | ||
| 07.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC | 270 | GlobeNewswire (Europe) | SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapyELI-002... ► Artikel lesen | |
| 27.10.25 | Krebstherapie von Elicio zeigt breite Immunantwort bei diversen HLA-Typen | 1 | Investing.com Deutsch | ||
| 27.10.25 | Elicio's cancer therapy shows immune response across diverse HLA types | 2 | Investing.com | ||
| 18.09.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 251 | GlobeNewswire (Europe) | BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,440 | 0,00 % | NanoRepro-Aktie: Eine neue Ära beginnt | Die NanoRepro-Aktie befindet sich seit dem Hoch im August letzten Jahres mit 2 € in einem langfristigen Abwärtstrend. Am Dienstag gewinnt sie aktuell +4% und steht bei rund 1,45 €. Das Lifestyle-Unternehmen... ► Artikel lesen | |
| OCUGEN | 1,552 | +1,97 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,250 | +0,33 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,360 | -6,85 % | COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on the development of natural... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 8,048 | -1,83 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 26.03.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 26.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 26.03.2026.ISIN NameCA2568277834 DOLLY... ► Artikel lesen | |
| IBIO | 1,822 | -1,67 % | iBio, Inc.: iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia | IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body compositionFirst participants expected to be dosed in 2Q 2026 SAN... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,710 | +0,54 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,810 | -0,12 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| CARDIFF ONCOLOGY | 1,356 | -1,60 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth | Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief... ► Artikel lesen | |
| MANNKIND | 2,322 | +0,48 % | Leerink reiterates Outperform on MannKind stock, sees overreaction | ||
| ALDEYRA | 1,550 | +1,97 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| TRAWS PHARMA | 1,550 | -1,27 % | hVIVO PLC - Influenza HCT contract signed with Traws Pharma | ||
| COHERUS ONCOLOGY | 1,492 | -1,97 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen |
Das Unternehmen ELICIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -11,56 % bei einem Aktienkurs von 8,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICIO THERAPEUTICS INC finden Sie auf Wallstreet Online.